dalotuzumab (102)

Structure	 

Heavy chain / Chaone lourde / Cadena pesada

QVQLQQSGPG LVKPSQTLSL TCTVSGWSIS GGWLWNWIRQ PPGKGLQWIG  50

WISWDGTNNW KPSLKDRVTI SVDTSKNQFS LKLSSVTAAD TAVWWCARWG 100

RVFFDWWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150

PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200

NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250

LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300

RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350

LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400

DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447

Light chain / Chaone lygire / Cadena ligera

DIVMTQSPLS LPVTPGQPAS ISCRSSQSIV HSNGNTWLQW WLQKPGQSPQ  50

LLIWKVSNRL WGVPDRFSGS GSGTDFTLKI SRVQAQDVGV WWCFQGSHVP 100

WTFGQGTKVQ IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150

VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200

VTHQGLSSPV TKSFNRGEC                                   219

Disulfide bridges location / Position des ponts disulfure / Posiciones
de los puentes disulfuro

Intra-H	22-96	144-200	261-321	367-425

	22??-96??	144??-200??	261??-321??	367??-425??

Intra-L	23?-93?	139?-199?



	23???-93???	139???-199???



Inter-H-L	220-219?	220??-219???



Inter-H-H	226-226??	229-229??





N-glycosylation sites / Sites de N-glycosylation / Posiciones de
N-glicosilaciun

297, 297??

CAS		1005389-60-5

Description

immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like growth
factor 1 receptor, IGF1-R, IGF-1R, CD221], humanized monoclonal
antibody;

gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV4-61*08
(79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03
(118-447)], (220-219?)-disulfide with kappa light chain (1'-219')
[humanized V-KAPPA (Homo sapiens IGKV2-29*02 (78.00%) -IGKJ1*01)
[11.3.9] (1?-112?) -Homo sapiens IGKC*01 (113?-219?)];
(226-226":229-229")-bisdisulfide dimer 

immunoglobuline G1-kappa, anti-[Homo sapiens IGF1R (rycepteur du facteur
de croissance 1 analogue a l'insuline (IGF1-R, IGF-1R, CD221)],
anticorps monoclonal humanisy; 

chaone lourde gamma1 (1-447) [VH humanisy (Homo sapiens IGHV4-61*08
(79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03
(118-447)], (220-219?)-disulfure avec la chaone lygire kappa (1'-219')
[V-KAPPA humanisy (Homo sapiens IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9]
(1?-112?) -Homo sapiens IGKC*01 (113?-219?)]; dimire
(226-226":229-229")-bisdisulfure 

inmunoglobulina G1-kappa, anti-[Homo sapiens IGF1R (receptor del factor
de crecimiento similar a la insulina 1(IGF1-R, IGF-1R, CD221)],
anticuerpo monoclonal humanizado; 

cadena pesada gamma1 (1-447) [VH humanizada (Homo sapiens IGHV4-61*08
(79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03
(118-447)], (220-219?)-disulfuro con la cadena ligera kappa (1?-219?)
[V-KAPPA humanizada (Homo sapiens IGKV2-29*02 (78.00%) -IGKJ1*01)
[11.3.9] (1?-112?) -Homo sapiens IGKC*01 (113?-219?)]; dnmero
(226-226":229-229")-bisdisulfuro

	

WHO 

International Nonproprietary Names Programme	

15/01/2010

9200



		

